Business Wire

FDA Approves REMICADE for Patients with Ankylosing Spondylitis, a Debilitating Inflammatory Condition of the Spine; Label Also Updated to Include Important Safety Information

MALVERN, Pa.--(BUSINESS WIRE)--Dec. 20, 2004--Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE(R) (infliximab) for the treatment of ankylosing ...
EurekAlert!

Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...
EurekAlert!

REMICADE becomes first anti-TNF biologic therapy to treat 1 million patients worldwide

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...
Healio

First-line Remicade effective in children with Crohn’s

Please provide your email address to receive an email when new articles are posted on . First-line Remicade therapy was superior to conventional treatment in achieving short-term remission in children ...
Healio

‘Pleasantly surprised’: Subcutaneous infliximab effective, regardless of Crohn’s location

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...
Medindia

New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease

SAN DIEGO, May 20 Data from a new analysis of the ActiveUlcerative Colitis Trials (ACT 1 and ACT 2) showed that at week 8, more than60 percent of patients with moderately to severely active ulcerative ...
Medindia

REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis

HORSHAM, Pa., Sept. 23, 2011 /PRNewswire/ -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE® (infliximab) for the treatment of moderately ...
Nature

Infliximab treatment strategy: dose titration based on response in patients with RA

Infliximab is an efficacious treatment for rheumatoid arthritis (RA). The recommended treatment schedule, however, is unsatisfactory in a substantial subset of patients. This study was an open-label ...
FierceBiotech

Humira Continues to Threaten Remicade’s Market-Leading Status in the Treatment of Crohn’s Disease

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the treatment of Crohn’s ...
Nature

Infliximab for GVHD therapy in children

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...
Monthly Prescribing Reference

The Potential Role of Infliximab, a TNF Inhibitor, in Treatment-Resistant Depression

The Potential Role of Infliximab, a TNF Inhibitor, in Treatment-Resistant Depression Infliximab, a monoclonal antibody ordinarily used to treat autoimmune diseases such as rheumatoid arthritis, may ...
Benzinga.com

Remicade Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis

), announced today that the U.S. Food and Drug Administration has approved Remicade for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an ...